Tonix Pharmaceuticals shares rise 14.41% in premarket after FDA approval of Tonmya for fibromyalgia treatment.

Tonix Pharmaceuticals Holding Corp. surged 14.41% in premarket trading after the FDA approved its drug Tonmya for treating fibromyalgia, the first new drug for the condition in 15 years. Tonix Pharmaceuticals focuses on fibromyalgia treatment, with Tonmya showing significant pain reduction and improved sleep and fatigue in phase three trials. The drug is expected to be commercialized in the fourth quarter of 2025, covering over 10 million adult patients in the U.S.